NCT07037277 - C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV | Biotech Hunter

Enrollment

880

Participants

Timeline

Start Date

June 2, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2027

Conditions

HEPATITIS C VIRUS CHRONIC INFECTIONHepatitis C, ChronicHepatitis C Virus InfectionHepatitis C

Interventions

DRUG

Bemnifosbuvir-Ruzasvir

BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis)

DRUG

Sofosbuvir-Velpatasvir

SOF/VEL Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 12 weeks

Trial Locations (9)

2025

RECRUITING

Atea Clinical Study Site, Chisinau

6001

RECRUITING

Atea Study Site, Port Elizabeth

7130

RECRUITING

Atea Study Site, Somerset West

9301

RECRUITING

Atea Study Site, Bloemfontein

47392

RECRUITING

Atea Study Site, Busan

49241

RECRUITING

Atea Study Site, Busan

0152

RECRUITING

Atea Study Site, Pretoria

0250

RECRUITING

Atea Study Site, Brits

120-752

RECRUITING

Atea Study Site, Seoul